



US 20210322570A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0322570 A1

SUNG et al.

(43) Pub. Date: Oct. 21, 2021

(54) GENE AND CELL THERAPY USING CELL FUSION TECHNOLOGY

(71) Applicant: CURAMYS INC., Seoul (KR)

(72) Inventors: Jung-Joon SUNG, Seoul (KR); Seung-Yong SEONG, Seoul (KR); Hee-Woo LEE, Seoul (KR); Ki Yoon KIM, Seoul (KR)

(21) Appl. No.: 17/358,774

(22) Filed: Jun. 25, 2021

Related U.S. Application Data

(63) Continuation of application No. 15/873,488, filed on Jan. 17, 2018, now Pat. No. 11,077,207, which is a continuation-in-part of application No. PCT/KR2016/007610, filed on Jul. 13, 2016.

Foreign Application Priority Data

Jul. 17, 2015 (KR) 10-2015-0101577

Publication Classification**(51) Int. Cl.**

A61K 48/00	(2006.01)
C07K 14/005	(2006.01)
A61K 35/545	(2006.01)
C12N 5/0775	(2006.01)
C12N 5/12	(2006.01)
C12N 5/0793	(2006.01)
C12N 15/85	(2006.01)

A61P 21/00 (2006.01)

A61P 25/00 (2006.01)

A61K 35/30 (2006.01)

C12N 5/0735 (2006.01)

C12N 5/074 (2006.01)

C12N 5/16 (2006.01)

C12N 9/24 (2006.01)

(52) U.S. Cl. CPC

A61K 48/005 (2013.01); A61K 38/00

(2013.01); A61K 35/545 (2013.01); C12N

5/0667 (2013.01); C12N 5/12 (2013.01);

C12N 5/0619 (2013.01); C12N 15/85

(2013.01); A61P 21/00 (2018.01); A61P 25/00

(2018.01); A61K 35/30 (2013.01); C12N

5/0606 (2013.01); C12N 5/0696 (2013.01);

C12N 5/16 (2013.01); C12N 9/2402

(2013.01); C12N 2760/18833 (2013.01); C07K

14/005 (2013.01)

(57)

ABSTRACT

The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells over-expressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Specification includes a Sequence Listing.